Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland

Swiss Medical Weekly

Volumn 140, Issue 9-10, 2010, Pages 146-152

  Overbeck, Kathrin ^a   Dufour, Jean Francois ^b   Müllhaupt, Beat ^c   Helbling, Beat ^d   Borovicka, Jan ^e   Malinverni, Raffael ^f   Heim, Markus ^g   Moradpour, Darius ^h   Cerny, Andreas ^a,i   Rickenbach, Martin ^j   Negro, Francesco ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Stadtspital Waid   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Hopital Pourtales Neuchatelois   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ Clinica Moncucco   (Switzerland)

^j SCCS Datacenter   (Switzerland)

more..

Author keywords

Barriers to treatment; Consensus guidelines; Hepatitis C treatment; Hepatitis C virus; Treatment decision making

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRACTICE GUIDELINE; QUESTIONNAIRE; SWITZERLAND;

EID: 77749242623     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-72.
2. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008;14(Suppl 2):S58-66.
3. Patel K, Muir AJ, McHutchinson J. Clinical Review: Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006; 332:1013-7.
4. Kanwal F, Hoang T, Brennan MR, Eisen S, Dominitz J, Gifford A, et al. Predictors of Treatment in Patients with Chronic Hepatitis C Infection - Role of Patient Versus Nonpatient Factors. Hepatology. 2007;46:1741-9.
5. Bini EJ, Bräu N, Currie S, Shen H, Anand B, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral therapy among4,084 US veterans with chronic hepatitis C infection. Am J Gastroenterol. 2005;100:1772-9.
6. Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland KR, et al. Clinical pathways for patients with newly diagnosed hepatitis C - What actually happens. J Viral Hep. 2006;13:264-71.
7. Butt AA, Justice AC, Skanderson M, O Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-9.
8. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users, Hepatology. 2001;34:188-93.
9. Robaeys G, Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18:159-66.
10. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002;67:117-23.
11. Van Thiel DH, Friedlander L, Molloy PJ. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7:165-8.
12. Chainuvati S, Khalid SK, Kancir S, Shea M, Edwards J, Sernyak M et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Vir Hepat. 2006;13:235-41.
13. National Institute of Health. NIH Consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
14. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. the 2002 French consensus. Gut. 2003;52:1784-7.
15. EASL International Consensus Conference on hepatitis C: Paris, 26-27 February 1999. Consensus Statement. J Hepatol. 1999;31:3-8.
16. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F; Swiss Hepatitis C Cohort Study Group. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007;36(4):731-7.
17. McHutchinson JR, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;359:1485-92.
18. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
19. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-82.
20. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for nontreatment of hepatitis C in veterans in care. J Viral Hepat. 2005; 12:81-5.
21. Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg D. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS. 2005;19:208-14.
22. Ouzan D, Cavailler P, Hofliger P, Mamino C, Joly H, Tran A. Modalities of care in anti HCV positive patients identified in General Medicine in the Alpes -Maritimes district. Gastroenterol Clin Biol. 2003;27:376-80.
23. Bochud M, Cornuz J, Vader J-P, Kamm W, Burnand B. Are internists in a non-prescriptive setting favorable to guidelines? Swiss Med Wkly. 2002;132:201-6.
24. Ho SB, Nguyen H, Tetrick LL. Influence of psychiatric diagnoses on interferon-a treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol. 2001;96:157-64.
25. Pariante CM, Orru MG, Baita A. Treatment with interferon-a in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354:131-2.
26. Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, et al. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther. 2006;24:1133-49.
27. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182:1595-601.
28. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, Mc-Cullough AJ, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002; 136:288-92.
29. Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, et al. Limited success of HCV antiviral therapy in United States Veterans. Am J Gastroenterol. 2002;97:149-55.
30. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Predinging response in hepatitis C virus therapy. Aliment Pharmacol Ther. 23:1043-54.
31. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313-20.
32. Thompson AJ, McHutchison JG.Antiviral resistance and specifically targeted therapy for HCV (STAT-C). Viral Hepat. 2009; 16:377-87.